UFF
LGND icon

USA Financial Formulas’s Ligand Pharmaceuticals LGND Stock Holding History

USA Financial Formulas’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-216
Closed -$43.1K – 481
2026
Q1 		$43.1K Sell
216
-11
-5% -$2.18K 0.01% 234
2025
Q4 		$42.9K Buy
+227
New +$43.6K 0.01% 241
2019
Q1 		– Sell
-3,535
Closed -$605K – 239
2018
Q4 		$605K Buy
+3,535
New +$377K 0.15% 106
2018
Q3 		– Sell
-882
Closed -$91K – 336
2018
Q2 		$91K Hold
882
– – 0.02% 296
2018
Q1 		$91K Buy
+882
New +$87.2K 0.02% 296
2015
Q4 		– Sell
-7,311
Closed -$391K – 112
2015
Q3 		$391K Buy
+7,311
New +$444K 0.25% 61

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

USA Financial Formulas's LGND Position: Q2 2026 in Review

USA Financial Formulas sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 216 shares — an estimated $43.1K sold.

USA Financial Formulas first reported a position in LGND in Q3 2015 and held it in 6 quarters. The position peaked at $605K in Q4 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • USA Financial Formulas reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • USA Financial Formulas sold 216 Ligand Pharmaceuticals shares in Q2 2026, an estimated $43.1K.
  • USA Financial Formulas first reported a position in Ligand Pharmaceuticals in Q3 2015 and held it in 6 quarters.
  • USA Financial Formulas's Ligand Pharmaceuticals position peaked at $605K in Q4 2018.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on USA Financial Formulas's 13F filing for Q2 2026, filed 4 Aug 2026.